Oxurion Receives Transparency Notification from Negma Group

March 2, 2023

Oxurion Receives Transparency Notification from Negma Group

Leuven, BELGIUM, Boston, MA, US – March 2, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Oxurion received a transparency notification on February 27, 2023 from Negma Group Ltd. indicating that as of February 20, 2023, it held 18,983,606 shares of the then outstanding 583,194,543 shares, and therefore crossed above the threshold (3%) by virtue of acquisition of voting securities. See Annex 1

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10	US Conway Communications Mary T. Conway [email protected]
" [email protected]
	ICR Westwicke Christopher Brinzey
Michael Dillen	Tel: +1 617 835 9304
Chief Business Officer Tel: +32 16 75 13 10	[email protected]
[email protected]

Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

________

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION Identification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by

A parent undertaking or a controlling person
5) Persons subject to the notification requirement
Name	Address (for legal entities)
Elaf Gassam
Negma Group Investment Ltd.	Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubai (United Arab Emirates) Craigmuir chambers, Road Town, Tortola, VG 1110 (British Virgin
Negma Group Ltd.	Islands)
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name	Address (for legal entities)

Please continue entering the information in part II concerning the Part II U persons referred to in Sections 5 and 6
7) Date on which the threshold is crossed
20/02/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
3 ¹
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

10) Notified details

$\overline{\phantom{a}}$

A) Voting rights	Previous notification	After the transaction
	# of voting rights		# of voting rights	% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Elaf Gassam				0.00%
Negma Group Investment Ltd.				0.00%
Negma Group Ltd.		18,983,606		3.26%
Subtotal		18,983,606		3.26%

$\ddot{}$

OTAI				.00%
$\approx$ Start with "arayon" of holders. Add subtotals with $\sum$ and then finish with the nersons who are "alone"

Start with "groups" of holders. Add subtotals with $L$ , and then rimsh with the proson for groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you ha

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement

	TOTAL			0	0.00%

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	18,983,606	3.26%

Holder		will cease to hold / will hold again	voting rights as of
13) Additional information




	Done at Dubai, United Arab Emirates
On		24/02/2023 (DD/MM/YYYY)
			and the con-

AI assistant

Oxurion NV Director's Dealing 2023

3987_mrq_2023-03-02_2ee7573e-af12-48ec-b377-9ae791f07bd7.pdf

Oxurion Receives Transparency Notification from Negma Group